Navigation Links
Bone Drugs May Beat Back Breast Cancer
Date:12/10/2009

Bisphosphonates seem to prevent recurrence, researchers find

THURSDAY, Dec. 10 (HealthDay News) -- Bone-building drugs used by tens of millions of women to fight osteoporosis also cut the risk of breast cancer, suggesting the drugs may play a dual role in keeping women healthy.

"Bone loss and potential fractures are a known complication of breast cancer therapy. Our feeling is that bisphosphonates may actually prevent disease recurrence through a variety of mechanisms," said Dr. Adam Brufsky, associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Brufsky authored one of several studies exploring the role of bone-building drugs in breast cancer prevention that were to be presented Thursday at the San Antonio Breast Cancer Symposium.

Bisphosphonates are already used to treat complications that result from breast cancer spreading to the bones.

One study looked at more than 150,000 postmenopausal women who participated in the U.S. government-led Women's Health Initiative (WHI).

The women taking bisphosphonates, namely Fosamax (alendronate), had a 32 percent reduction in their rate of invasive breast cancer compared to women who were not taking one of these drugs.

The University of California, Los Angeles, researchers were able to control for the fact that women with low bone mineral density are already at lower risk for breast cancer.

Because the study was not a randomized, controlled one, said lead investigator Dr. Rowan Chlebowski, a professor and medical oncologist with UCLA, "the findings are not definitive but they do provide a strong signal."

In another study, Israeli researchers found that postmenopausal women taking bisphosphonates for one or more years had a 29 percent reduction in their risk of breast cancer.

And the tumors that did appear tended to be estrogen receptor-positive and thus easier to treat than estrogen receptor-negative tumors.

And in other news from the symposium:

  • Researchers from the University of Pittsburgh Cancer Institute, led by Brufsky, concluded that zoledronic acid, another bisphosphonate, is safe and effective for use by postmenopausal women with breast cancer who are being treated with aromatase inhibitors. Bone mineral density increased 6.2 percent in women taking zoledronic acid, compared with 2.4 percent in the control group. Fractures were also reduced slightly in the treatment group, but it's unclear how significant this was. Zoledronic acid is marketed under several brand names, including Zometa.
  • A new drug, denosumab, a monoclonal antibody, performed better than zoledronic acid in easing problems associated with the spread of breast cancer to the bones.
  • A final study found that it was safe to give zoledronic acid to women with breast cancer being treated with the aromatase inhibitor Femara (letrozole) before surgery. No clear indication emerged as to whether the dual treatment was effective, however.

More information

The National Cancer Institute has more on breast cancer.



SOURCES: Dec. 9, 2009, teleconference with: Rowan Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, and Adam Brufsky, M.D., Ph.D., associate professor, medicine, associate chief, hematology-oncology, and associate director, clinical investigation, University of Pittsburgh Cancer Institute


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AIDS Drugs Dont Need Routine Lab Monitoring
2. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
3. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
4. OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
5. Second-line CML drugs evoke faster response than front-line therapy
6. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
7. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
8. Diabetes Drugs Go Head-to-Head in Study
9. drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
10. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
11. Coverage of inexpensive drugs may increase length and quality of life after heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Providing for ... understand the estate planning process, or where to even begin. “Now more than ever ... you are to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
(Date:4/21/2017)... ... ... Each year, everyone is urged to give back to the earth on April ... a better future. However, supporting the environment should be an everyday practice. , ... to five times more polluted than outdoor air, reports the Environmental Protection Agency -- ...
(Date:4/21/2017)... Houston, Texas (PRWEB) , ... April 21, 2017 ... ... repeal…. sound familiar? These are five common elements between the Obamacare program ... feral hog control program which uses Warfarin poison to kill hogs. , ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana ... significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit ... IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: